PHAR - יחס חוב להיוון בספרים Pharming Group NV

Pharming Group N.V. (PHAR) relies on the expertise of top biologists motivated by the actual saving of lives. The business model is based on patients' total dependence on exclusive medications, while profitability is limited by government oversight and stands at 0.49. The company also implements green chemistry and bioethics during drug development. This PHAR price chart clearly visualizes the market dynamics of this immune therapy manufacturer.

This indicator determines the proportion of debt relative to equity based on book value, allowing for an assessment of actual financial leverage without the influence of market volatility. The stable current balance sheet leverage ratio confirms the ability of Pharming Group N.V. (PHAR) to finance the expansion of orphan drugs using its own resources, minimizing credit risks while scaling global sales.